Instil Current Deferred Revenue from 2010 to 2024
| TIL Stock | USD 26.91 2.79 9.39% |
Check Instil Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Instil Bio's main balance sheet or income statement drivers, such as Net Interest Income of 4.7 M, Interest Income of 8.9 M or Depreciation And Amortization of 3 M, as well as many indicators such as Price To Sales Ratio of 19.7 K, Dividend Yield of 0.0 or PTB Ratio of 0.23. Instil financial statements analysis is a perfect complement when working with Instil Bio Valuation or Volatility modules.
Instil | Current Deferred Revenue |
About Instil Bio Financial Statements
Instil Bio investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Instil Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 463 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Instil Bio Correlation against competitors. For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instil Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.56) | Return On Assets (0.12) | Return On Equity (0.49) |
The market value of Instil Bio is measured differently than its book value, which is the value of Instil that is recorded on the company's balance sheet. Investors also form their own opinion of Instil Bio's value that differs from its market value or its book value, called intrinsic value, which is Instil Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instil Bio's market value can be influenced by many factors that don't directly affect Instil Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.